The gastroparesis market in North America is expected to grow from US$ 1,488.03 million in 2020 to US$ 2,032.27 million by 2027; it is estimated to grow at a CAGR of 4.6% from 2020 to 2027.
The US, Canada, and Mexico are major economies in North America. Growing diabetes mellitus prevalence is the major factor driving the growth of the North America gastroparesis market. Diabetes mellitus is a life-threatening chronic disease mainly caused by the body’s inability to produce insulin or effectively utilize it. Diabetes is one of the health emergencies of the 21st century. According to a report published by International Diabetes Federation (IDF) in 2019, 1 in 11 people in the world are suffering from diabetes. In addition, the National Institutes of Health (NIH) also reported that the incidence of type 1 diabetes is increasing rapidly, and the disease is affecting a significant number of children and teenagers. Diabetes is one of the prominent known causes of gastroparesis. The condition is characterized by damaged nerves, especially involving vagus nerves and stomach wall cells. The damage to vagus nerves affects muscle motility of stomach and small intestine. According to a study published by Johns Hopkins University, ~30–50% of the diabetic population suffers from delayed gastric emptying. The escalating incidence of diabetes mellitus due to obesity, sedentary lifestyle, and unhealthy eating habits is propelling the prevalence of gastroparesis.
Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing a growing number of COVID-19 cases since its outbreak. In patients with chronic GI illnesses, COVID-19 may initially present as a flare of their underlying GI conditions as viruses have historically been implicated in exacerbations of GI disorders, including gastroparesis. Moreover, according to the world gastroenterology organization, there has been observed a rise in GI complications after COVID-19 symptoms. Patients with COVID-19 may complain of digestive symptoms such as poor appetite, nausea, vomiting, diarrhea, symptoms, or disease activity for pre-existing digestive diseases such as inflammatory bowel disease.However, according to a review of Diabetic Gastroparesis for the Community Pharmacist published in 2016, over 29.1 million people in the US have diabetes and have faced with the complications associated with the disease. Diabetes is the most common systemic disease that causes gastroparesis. Moreover, according to data published by National Center for Biotechnology Information (NCBI) in September 2020, nausea and vomiting from detailed consideration as symptoms of COVID‐19 is surprising as it can be an early presenting symptom. Thus, there has been observed a rise in the sale of prokinetic agents and antiemetic agents. However, due to disruption in supply chain and governmental orders restricting certain activities in response to COVID-19, including changes in on-site operations to reduce manufacturing capacity and implement social distancing, reductions in suppliers’ ability to source, ship raw materials in alignment with demands, work stoppages, slowdowns, and delays, the market may show a slowdown.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America gastroparesis market. The North America gastroparesis market is expected to grow at a good CAGR during the forecast period.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
North America Gastroparesis Market Segmentation
North America Gastroparesis Market – By Type
- Idiopathic
- Diabetic
- Post-surgical
- Others
North America Gastroparesis Market – By Drug Class
- Prokinetic Agents
- Botulinum Toxin Injections
- Antiemetic Agent
North America Gastroparesis Market – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
North America Gastroparesis Market, by Country
- US
- Canada
- Mexico
North America Gastroparesis Market - Companies Mentioned
- Allergan Plc
- ANI Pharmaceuticals, Inc.
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Cinrx Pharma, LLC (Cindome Pharma)
- EVOKE PHARMA
- Ipca Laboratories Ltd.
- Johnson and Johnson Services, Inc.
- NEUROGASTRX, INC.
- Pfizer Inc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Drug Class, and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
US, Canada
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Gastroparesis Market – By Type
1.3.2 North America Gastroparesis Market – By Drug Class Type
1.3.3 North America Gastroparesis Market – By Distribution Channel
1.3.4 North America Gastroparesis Market – By Country
2. North America Gastroparesis Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Gastroparesis Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert Opinion
5. North America Gastroparesis Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Diabetes Mellitus Prevalence
5.1.2 Rising Geriatric Population
5.2 Market Restraints
5.2.1 Side Effects Associated with Gastroparesis Drugs
5.3 Market Opportunities
5.3.1 Rising Investments and Financial Assistance Related to Research
5.4 Future Trends
5.4.1 Gastric Electrical Stimulation Therapy Research Getting Popular
5.5 Impact Analysis
6. Gastroparesis Market – North America Analysis
6.1 North America Gastroparesis Market Revenue Forecast and Analysis
7. North America Gastroparesis Market Analysis – By Type
7.1 Overview
7.2 North America Gastroparesis Market Revenue Share, by Type (2019 and 2027)
7.3 Idiopathic
7.3.1 Overview
7.3.2 Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Diabetic
7.4.1 Overview
7.4.2 Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Post-Surgical
7.5.1 Overview
7.5.2 Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8. North America Gastroparesis Market Analysis – By Drug Class Type
8.1 Overview
8.2 North America Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
8.3 Prokinetic Agents
8.3.1 Overview
8.3.2 Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Botulinum Toxin Injection
8.4.1 Overview
8.4.2 Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Antiemetic Agents
8.5.1 Overview
8.5.2 Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9. North America Gastroparesis Market Analysis – By Distribution Channel
9.1 Overview
9.2 North America Gastroparesis Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
10. North America Gastroparesis Market – Country Analysis
10.1 Overview
10.1.1 North America: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.1.2 US: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.2.1 US: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.2.2 US Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.2.3 US Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.2.4 US Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.3 Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.1 Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.2 Canada Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.3.3 Canada Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.3.4 Canada Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.4 Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.1 Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.2 Mexico Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.3 Mexico Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.4 Mexico Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on North America Gastroparesis Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. Gastroparesis Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Gastroparesis Market, 2018-2020
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Evoke Pharma
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Allergan Plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 NEUROGASTRX, INC.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bausch Health Companies Inc. (Salix Pharmaceuticals)
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson and Johnson Services, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 ANI Pharmaceuticals, Inc.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Ipca Laboratories Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 CinRx Pharma, LLC (CinDome Pharma)
13.10.1 Business Description
13.10.2 Products and Services
13.10.3 Financial Overview
13.10.4 SWOT Analysis
13.10.5 Key Developments
14. Appendix
14.1 About the Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. US Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 2. US Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 3. US Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 4. Canada Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 5. Canada Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 6. Canada Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 7. Mexico Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 8. Mexico Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 9. Mexico Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 10. Recent Inorganic Growth Strategies in the Gastroparesis market
Table 11. Recent Organic Growth Strategies In the Gastroparesis market
Table 12. Glossary of Terms, North America Gastroparesis Market
LIST OF FIGURES
Figure 1. North America Gastroparesis Market Segmentation
Figure 2. North America Gastroparesis Market Segmentation, By Country
Figure 3. North America Gastroparesis Market Overview
Figure 4. Idiopathic Segment Held Largest Share of North America Gastroparesis Market
Figure 5. US to Show Remarkable Growth During Forecast Period
Figure 6. North America PEST Analysis
Figure 7. North America Gastroparesis Market Impact Analysis of Drivers and Restraints
Figure 8. North America Gastroparesis Market – Revenue Forecast And Analysis – 2019- 2027
Figure 9. North America Gastroparesis Market Revenue Share, by Type (2019 and 2027)
Figure 10. North America Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. North America Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. North America Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 13. North America Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. North America Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
Figure 15. North America Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 16. North America Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. North America Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. North America Gastroparesis Market Share, by Distribution Channel, 2019 and 2027 (%)
Figure 19. North America Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. North America Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. North America Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. North America: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)
Figure 23. North America: Gastroparesis Market, by Country, 2019 & 2027 (%)
Figure 24. US: Pharmaceutical Drug Delivery market – Revenue and Forecast to 2027 (USD Million)
Figure 25. Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 26. Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 27. Impact of COVID-19 Pandemic in North American Country Markets
Figure 28. Growth Strategies in the Gastroparesis Market, 2018-2020
- Allergan Plc
- ANI Pharmaceuticals, Inc.
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Cinrx Pharma, LLC (Cindome Pharma)
- EVOKE PHARMA
- Ipca Laboratories Ltd.
- Johnson and Johnson Services, Inc.
- NEUROGASTRX, INC.
- Pfizer Inc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For